CTLA4 and neoplasm: Notably, sole application of the anti-CTLA-4, anti-PD-1, and/or anti-HSP90 molecules used either alone or in combination with each other did not markedly impact on the numbers of Treg and T17 lymphocytes recovered from the tumorous tissues (Figure 6A–F).